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to be statistically significant (odds ratio: 1.056; 95%CI: 0.669-1.665) between atypical
and typical antipsychotic users. Similar results were obtained in sensitivity anal-
ysis (odds ratio: 1.089; 95% CI: 0.775-1.530). CONCLUSIONS: Typical and atypical
antipsychotic drug use in an elderly Medicare population has similar risks of hip
fracture.
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OBJECTIVES:The study evaluated the risk of falls and fractures associatedwith use
of risperidone, olanzapine and quetiapine among community-dwelling older
adults in the US. METHODS: The study involved a multiple propensity score-ad-
justed retrospective cohort design and included older adults aged 50 years and
above, who initiated prescriptions of risperidone, olanzapine or quetiapine be-
tween July 1, 2000 and June 30, 2008 using IMS LifeLink Health Plans Claims data-
base. Patients were followed until hospitalization/emergency room (ER) visit for
accidental fall/hip fracture, or the end of the study period, whichever occurred
earlier. Propensity score-adjusted Cox proportional hazard regression model was
used to evaluate the relative risk of falls or fractures. The covariates in the final
model included maximum dose of antipsychotic therapy, and exposure to other
psychotropic medications that increase the risk of falls or fractures. RESULTS:
There were 12,145 (5,083 risperidone, 4,377 olanzapine and 2,685 quetiapine) new
users of atypical agents. A total of 380 cases of falls or fractures with at least one
hospitalization/ ER visit following the use of antipsychotic agents were identified.
The number of falls or fractures for risperidone, olanzapine and quetiapine were
165 (3.65%), 109 (2.81%) and 106 (4.47%) respectively. After adjusting for propensity
scores and other covariates, the Cox proportional hazardmodel showed that there
was no statistically significant difference with use of risperidone (hazard ratio,
HR-1.11; 95% CI- 0.85-1.45) or quetiapine (HR-1.16; CI-0.87-1.53) compared to olan-
zapine in the risk of falls or fractures. CONCLUSIONS: The study found no signifi-
cant difference across the individual atypical agents in the risk of falls or fractures
in a large cohort of older adults. Future studies are required to evaluate the overall
safety profiles of atypical antipsychotics in the above population.
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OBJECTIVES: Attention deficit hyperactivity disorder (ADHD) is a common psychi-
atric disorder of childhood, and the methylphenidate hydrochloride (MPH) is the
most frequently and well-established prescribed pharmacotherapy for ADHD.
Warnings by the United States Food and Drug Administration on psychiatric ad-
verse effects have concerns for drug safety. Existing studies to date demonstrate
that MPH’s safety of children with ADHD which get inconsistent results. The pur-
pose was to evaluate the potential association between MPH treatment and the
subsequent development of psychiatric disorders such as disruptive, anxiety,
mood, learning, tic and substance-related disorders. METHODS: A retrospective
cohort studywas conducted. Study subjects selectedwere aged 6 to 18 years on the
date of the first diagnosed for ADHD between 2001 and 2006. Patients were divided
into 2 groups: ever-using MPH and not-using MPH. The authors conducted case-
control matching on the propensity score to reduce selection bias. The Cox Propor-
tional Hazards Model was used to assess the association of use of MPH with the
subsequent risks of psychiatric events occurring. RESULTS: The results shows that
the MPH group had a significantly higher hazard ratio (HR) of patients diagnosed
with oppositional defiant disorder (ODD) (HR  1.807, P  0.001), conduct disorder
(CD) (HR 1.225, P 0.0460), and anxiety disorders (AD) (HR 1.921, P 0.001). The
MPH group had a significantly lower HR of patients diagnosed with learning disor-
ders (LD) (HR 0.818, P 0.0029). In addition, the authors found theMPH group had
a significantly higher HRs of ODD and CD and a significantly lower HR of LD in boys
only. CONCLUSIONS: Our study found that MPH treatment is associated with a
higher risk of development of oppositional defiant disorder, conduct disorder and
anxiety disorders and a lower risk of learning disorders.
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OBJECTIVES: Antidepressants are first line treatment for depression. Effectiveness
may be compromised because of discontinuation, which is commonly associated
with side effects. Using a national database of medical and pharmacy claims, we
sought to identify and compare the prevalence of side effects in newly depressed
adult and adolescent patients taking different classes of antidepressants.
METHODS: A new-user design was implemented using 11 years of data to identify
a retrospective cohort of newly depressed subjects on antidepressant mono-
therapy, defined as SSRI, SNRI, TCA, MAOI, buproprion, phenylpiperazine, or tet-
racyclic. Rates of side effects (per 1,000 person-months of exposure) were calcu-
lated within each antidepressant group; relative risks were calculated (SSRI as
referent group). Propensity-adjusted Cox Proportional Hazards regression was
used to model the likelhood of side effects adjusted for demographic, clinical and
treatment characteristics. RESULTS:A total of 40,017 patients had a new episode of
depression and were on antidepressant monotherapy within 30 days of diagnosis
[SSRI (66%), Bupropion (14%), SNRI (12%), other (8%)]. Themost common side effects
were headache (up to 16.8 per 1,000 person-months of therapy in adults, 17.6 per
1,000 in adolescents) and nausea (up to 7.2 per 1,000 in adults, 9.3 per 1,000 in
adolescents). Relative to adults receiving SSRIs, those receiving SNRIs had higher
risk of nausea (HR1.28, 95%CI1.08-1.52), and of having one ormore side effect of
any type (HR1.23, 95%CI1.10-1.37). Adults taking bupropion were less likely to
have sedation (HR0.36, 95%CI0.16-0.79). Adolescent receiving an SNRI were
more likely to experience sedation compared to adolescents receiving an SSRI
(HR3.14, 95%CI1.01-9.82). CONCLUSIONS: Side effects detected in claims must
be significant enough to be reported to the provider and medically coded, so these
rates are underestimates. Nevertheless, the reported rates are nontrivial. Future
work will account for side effects in the likelihood of discontinuation and associ-
ated reduced comparative effectiveness.
PMH7
LIKELIHOOD OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PERSONS
INITIATING THERAPY WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS:
EFFECT OF INITIAL SSRI AND OTHER FACTORS
Valuck RJ1, Libby AM1, Anderson HD1, Erder M2, Milea D3, Doshi JA4, Collins C5,
Preskorn S6
1University of Colorado, Denver, Aurora, CO, USA, 2Shire Pharmaceuticals, Wayne, PA, USA,
3Lundbeck SAS, Issy-les-Moulineaux, France, 4University of Pennsylvania, Philadelphia, PA, USA,
5University of Washington, Seattle, WA, USA, 6Clinical Research Institute, Wichita, KS, USA
OBJECTIVES: Selective Serotonin Reuptake Inhibitors (SSRIs) are widely used anti-
depressants. Pharmacokinetic and pharmacodynamic differences among the SS-
RIs can give rise to differences in drug-drug interaction (DDI) potential. This study
estimated the effect of initial SSRI choice on the likelihood of receiving a potentially
interacting drug (and thus a potential SSRI-DDI) among subjects initiating therapy
with SSRIs in the United States managed health care plans. METHODS: Using a
large health insurance claims database (IMS LifeLink Database), we examined ret-
rospective cohorts of new SSRI users between 2002-2008. For each new SSRI user,
we used medical and pharmacy claims to identify instances and crude rates of
potential SSRI-DDI according to compendia and expert panel based lists of inter-
actions. We calculated crude and adjusted incidence rate ratios for potential SSRI-
DDI based on the initial SSRI prescribed, adjusting for demographic, clinical, and
prescriber related factors, length of SSRI exposure and propensity for receiving
escitalopram as the initial SSRI using Poisson regression methods. RESULTS: A
total of 913,619 subjects met inclusion criteria. Using the compendia list of SSRI-
DDI, 48.5-62.0% of subjects had at least one instance of coprescribing of potentially
interacting drug(s) with SSRI. Compared to escitalopram users, citalopram (HR
[Hazard Ratio]1.05, p0.01), fluoxetine (HR1.03, p0.01), fluvoxamine (HR1.17,
p0.01), and paroxetine (HR1.05, p0.01) users all demonstrated a higher likeli-
hood of potential SSRI-DDI. Sertraline (HR0.99, p0.32) users demonstrated a
similar likelihood of potential SSRI-DDI as escitalopram. Results were similar for
the expert panel list of SSRI-DDI. CONCLUSIONS: SSRIs are widely used, and co-
prescribing of drugs with the potential to elicit SSRI-DDI may be more frequent
than is often reported. Among SSRIs, escitalopram and sertraline are associated
with a lower likelihood of being co-prescribed with a potentially interacting drug.
Clinicians, pharmacists and patients should be aware of the potential for such
interactions, and further study is needed to identify subsequent patient outcomes.
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OBJECTIVES: Research shows a significant association between low bone mineral
density (BMD) and persons receiving antidepressant medication, with levels of
BMD loss varying with the type of pharmacological agent used. This study com-
pared the BMD of depressed patients on different groups of antidepressants.
METHODS: One hundred forty male and female depressed subjects between the
ages of 25 – 70 years were recruited from the psychiatric clinics in Penang General
Hospital and Penang Adventist Hospital. The groups of antidepressant medication
included selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants
(TCA) and other types of antidepressants (OTA). BMD was ascertained by measur-
ing the quantitative ultrasound derivative Z-score from the calcaneal bone of the
heel using an Ultrasound bone densitometer by Furuno Electric. RESULTS: ANOVA
found no significant differences in mean BMD across the different groups of anti-
depressants (p=0.055). CONCLUSIONS: This study finds no association between
BMD loss and the type of antidepressant employed in a depressed Malaysian pop-
ulation.
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OBJECTIVES: Antipsychotic use among dual eligible nursing home residents is a
cost and safety concern. This study examined the comparative risk of death in dual
eligible elderly nursing home residents using typical and atypical agents.
METHODS:A retrospective cohort designmatched on propensity scorewas used to
examine the risk of death due to antipsychotic use among dual eligible nursing
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